Loading...
Loading...
Concert Pharmaceuticals, Inc.
CNCE today announced that it has
received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The
payment is pursuant to a September 2011 patent assignment agreement between
Concert and Auspex whereby Concert assigned to Auspex a U.S. patent
application relating to deuterium-substituted analogs of pirfenidone. Under
the agreement, Concert became eligible to receive the payment due to a
change of control of Auspex, which was acquired by Teva Pharmaceuticals
Industries Ltd on May 5, 2015.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in